| Revista: | International braz j urol |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000296833 |
| ISSN: | 1677-5538 |
| Autors: | Dmochowski, Roger R1 Starkman, Jonathan S Davila, G. Willy |
| Institucions: | 1Vanderbilt University, Cleveland Clinic Foundation, Weston, Florida. Estados Unidos de América |
| Any: | 2006 |
| Període: | Sep-Oct |
| Volum: | 32 |
| Número: | 5 |
| Paginació: | 513-520 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Teórico, descriptivo |
| Resumen en inglés | Overactive bladder is commonly treated with oral anticholinergic drugs such as oxybutynin chloride. Although oral anticholinergic agents have been effective in controlling urinary urgency and incontinence, adverse events, particularly dry mouth, often cause patients to discontinue oral therapy and to endure incontinence. Oxybutynin can be delivered transcutaneously, maintaining the efficacy of oral oxybutynin while significantly minimizing side effects (e.g., dry mouth) that may complicate therapy. By avoiding hepatic and gastrointestinal metabolism of oxybutynin, less N-desethyloxybutynin (N-DEO) is produced and this compound is deemed to be responsible for anticholinergic side effects such as dry mouth. This novel oxybutynin formulation offers patients with OAB and urge urinary incontinence a well-tolerated option for managing the symptoms of overactive bladder |
| Disciplines | Medicina |
| Paraules clau: | Cirugía, Terapéutica y rehabilitación, Incontinencia urinaria, Oxibutinina, Vejiga hiperactiva |
| Keyword: | Medicine, Surgery, Therapeutics and rehabilitation, Urinary incontinence, Oxybutynin, Hyperactive bladder |
| Text complet: | Texto completo (Ver HTML) |
